TTC staining showed that treatment of GLYX-13 + Ro-2569819 (selective NR2B antagonist 5 mg/kg) after MCAO failed to present additional neuro-protective effect compared to GLYX-13 intervention alone (G + R 17.45 ± 1.442% vs. GLYX-13 17 ± 3.468% n = 6, p > 0.05); by contrast treatment of GLYX-13 + NVP-AAM077 (selective NR2A antagonist 2.4 mg/kg) completely reversed the amelioration of cerebral infarction elicited by GLYX-13 (G + N 46.79 ± 4.620% vs. GLYX-13 17 ± 3.468%; Figure 12). Here, GRIN2A is linked to cerebral infarction.